Neuros Technology

Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

Wednesday, September 15, 2021 - 4:15pm

QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.

Key Points: 
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.
  • Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.
  • Neuros Medical, a neuromodulation company, has developed the Altius system for the treatment of chronic post-amputation pain (phantom limb pain and residual limb pain).
  • Post-amputation pain includes both phantom limb and residual limb (or "stump") pain, and impacts nearly one million Americans.

ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel

Wednesday, March 24, 2021 - 8:05pm

Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuros Chief Executive Officer, and serve as a member of the Companys senior leadership team.

Key Points: 
  • Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuros Chief Executive Officer, and serve as a member of the Companys senior leadership team.
  • Ellisa is a tremendous addition to our capable and growing leadership team, commented Joe Burnett, President and CEO of ClearPoint Neuro.
  • Ms. Cholapranee brings to the Company almost a decade of experience advising companies in the life science and medical device sectors on legal, business, and compliance issues.
  • I am thrilled to join ClearPoint at such an exciting phase of the Companys growth, stated Ellisa Cholapranee.

Biotechnology Leader and Surgeon Dr. Matthew Klein Joins ClearPoint Neuro Board of Directors

Friday, April 17, 2020 - 1:10pm

IRVINE, Calif., April 17, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuros Board of Directors effective immediately.

Key Points: 
  • IRVINE, Calif., April 17, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuros Board of Directors effective immediately.
  • Dr. Klein, Chief Development Officer of PTC Therapeutics, Inc. (PTC), is a veteran biotechnology company executive with extensive experience in drug discovery and development, and a board-certified surgeon.
  • He succeeds Marcio Souza, who joined ClearPoint Neuros Board as PTCs representative in connection with PTCs May 2019 equity investment in ClearPoint Neuro.
  • The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the United States.